MLYSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Mineralys Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$20.92+0.62 (+3.05%)
Close on Oct 19, 2026
- Market cap
- $1.77B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$22.64 (−51.97%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $1.77B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.22
- Dividend yield
- –
- Free cash flow yield
- -8.04%
Fundamentals
- Net income
- -$349.58M
- EPS, diluted
- -$4.24
- Free cash flow
- -$142.43M
- Book value per share
- $6.50
- Diluted shares
- 85M
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Operating income
-$370.79M
Net income
-$349.58M
EPS, diluted
-$4.24
Free cash flow
–
Reported periodTrailing twelve months